1-20 of 24
John E. Godwin, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity Setting: Initial Results from the Outreach Study

John E. Godwin, MD, Cesar O. Freytes, MD, Michael Maris, MD, Don A. Stevens, MD, Daanish Hoda, MD, Bassam Mattar, MD, Juan C. Varela, MDPhD, Mohamad Cherry, MDMS, James Essell, MD, Jay Courtright, MD, Suzanne R. Fanning, DO, Habte A. Yimer, MD, Nikolaus S. Trede, MD PhD, Marina Youssef, PharmD, James Lymp, PhD, Carlos Bachier, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 50–52.
https://doi.org/10.1182/blood-2020-136640
Published: 2020
Journal Articles

Immune Senescence and Exhaustion Correlate with Response to Flotetuzumab, an Investigational CD123×CD3 Bispecific Dart® Molecule, in Acute Myeloid Leukemia

Jayakumar Vadakekolathu, PhD, Tung On Yau, Sarah E. Church, PhD, Michael P. Rettig, PhD, Ibrahim Aldoss, MD, Geoffrey L Uy, MD, Norbert Vey, MD, Ashkan Emadi, MD, PhD, Peter H. Sayre, MDPhD, Roland B. Walter, MDPhDMS, Matthew C Foster, MD, Martha L. Arellano, MD, John E. Godwin, MD, Matthew J. Wieduwilt, MD PhD, Michael T. Byrne, DO, Laura C. Michaelis, MD, Patrick J. Stiff, MD, Matteo Giovanni Carrabba, MD, Patrice Chevalier, MD PhD, Emmanuel Gyan, MD PhD, Christian Recher, MD PhD, Anjali S Advani, MD, Martin Wermke, Harry P. Erba, Fabio Ciceri, MD, Geert Huls, MD PhD, Mojca Jongen-Lavrencic, MD PhD, Farhad Ravandi, MBBS, Antonio Curti, MDPhD, Max S. Topp, MD, John Muth, MS, Patrick Kaminker, PhD, Bob Lowenberg, MDPhD, Ivana Gojo, MD, Leo Luznik, MD, John F. DiPersio, MD PhD, Jan K Davidson-Moncada, MDPhD, Sergio Rutella, MDPhDFRCPath
Journal: Blood
Blood (2020) 136 (Supplement 1): 26–28.
https://doi.org/10.1182/blood-2020-134921
Published: 2020
Journal Articles

Prophylactic Ruxolitinib for Cytokine Release Syndrome (CRS) in Relapse/Refractory (R/R) AML Patients Treated with Flotetuzumab

Geoffrey L Uy, MD, Michael P. Rettig, PhD, Stephanie Christ, MS, Ibrahim Aldoss, MD, Michael T. Byrne, DO, Harry P. Erba, MD PhD, Martha L. Arellano, MD, Matthew C Foster, MD, John E. Godwin, MD, Farhad Ravandi, MBBS, Peter H. Sayre, MDPhD, Anjali S Advani, MD, Matthew J. Wieduwilt, MD PhD, Ashkan Emadi, MD, PhD, Laura C. Michaelis, MD, Patrick J. Stiff, MD, Martin Wermke, Norbert Vey, MD, Patrice Chevalier, MD PhD, Emmanuel Gyan, MD PhD, Christian Recher, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Antonio Curti, MDPhD, Geert Huls, MD PhD, Max S. Topp, MD, Mojca Jongen-Lavrencic, MD PhD, John Muth, MS, Teia Curtis, Mary Beth Collins, Erin Timmeny, Kuo Guo, MSc, Jian Zhao, PhD, Kathy Tran, Patrick Kaminker, PhD, Priyanka Patel, PharmD, Ouiam Bakkacha, MD, Kenneth Jacobs, MD, Maya Kostova, PhD, Jennifer Seiler, PhD RAC, Bob Lowenberg, MDPhD, Sergio Rutella, MDPhDFRCPath, Roland B. Walter, MDPhDMS, Ezio Bonvini, MD, Jan K Davidson-Moncada, MDPhD, John F. DiPersio, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 19–21.
https://doi.org/10.1182/blood-2020-134612
Published: 2020
Journal Articles

TP53 Abnormalities Correlate with Immune Infiltration and Associate with Response to Flotetuzumab Immunotherapy in Acute Myeloid Leukemia

Catherine Lai, MD MPH, Jayakumar Vadakekolathu, PhD, Stephen Reeder, BSc, Sarah E. Church, PhD, Carmen Ballesteros-Merino, PhD, Ibrahim Aldoss, MD, Anjali S Advani, MD, John E. Godwin, MD, Matthew J. Wieduwilt, MD PhD, Martha L. Arellano, MD, Geoffrey L Uy, MD, Farhad Ravandi, MBBS, Matthew C Foster, MD, Emmanuel Gyan, MD PhD, Patrick J. Stiff, MD, Norbert Vey, MD, Ashkan Emadi, MD, PhD, Matteo Giovanni Carrabba, MD, Roland B. Walter, MDPhDMS, Peter H. Sayre, MDPhD, Kathy Tran, Erin Timmeny, Michael P. Rettig, PhD, Patrick Kaminker, PhD, John Muth, MS, Kuo Guo, MSc, Tung On Yau, Peter J.M. Valk, PhD, Bob Lowenberg, MDPhD, Ivana Gojo, MD, Martin Bornhäuser, MD, John F. DiPersio, MD PhD, Jan K Davidson-Moncada, MDPhD, Sergio Rutella, MDPhDFRCPath
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–4.
https://doi.org/10.1182/blood-2020-136919
Published: 2020
Journal Articles

Flotetuzumab As Salvage Therapy for Primary Induction Failure and Early Relapse Acute Myeloid Leukemia

Ibrahim Aldoss, MD, Geoffrey L Uy, MD, Norbert Vey, MD, Ashkan Emadi, MD, PhD, Peter H. Sayre, MDPhD, Roland B. Walter, MDPhDMS, Matthew C Foster, MD, Martha L. Arellano, MD, John E. Godwin, MD, Matthew J. Wieduwilt, MD PhD, Michael T. Byrne, DO, Laura C. Michaelis, MD, Patrick J. Stiff, MD, Matteo Giovanni Carrabba, MD, Patrice Chevalier, MD PhD, Emmanuel Gyan, MD PhD, Christian Recher, MD PhD, Anjali S Advani, MD, Martin Wermke, Harry P. Erba, Fabio Ciceri, MD, Geert Huls, MD PhD, Mojca Jongen-Lavrencic, MD PhD, Max S. Topp, MD, Antonio Curti, MDPhD, Farhad Ravandi, MBBS, Michael P. Rettig, PhD, John Muth, MS, Mary Beth Collins, Erin Timmeny, Kuo Guo, MSc, Jian Zhao, PhD, Kathy Tran, Patrick Kaminker, PhD, Priyanka Patel, PharmD, Ouiam Bakkacha, MD, Teia Curtis, Kenneth Jacobs, MD, Maya Kostova, PhD, Jennifer Seiler, PhD RAC, Bob Lowenberg, MDPhD, Sergio Rutella, MDPhDFRCPath, Ezio Bonvini, MD, Jan K Davidson-Moncada, MDPhD, John F. DiPersio, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–18.
https://doi.org/10.1182/blood-2020-134576
Published: 2020
Journal Articles

Flotetuzumab (FLZ), an Investigational CD123 x CD3 Bispecific Dart® Protein-Induced Clustering of CD3+ T Cells and CD123+ AML Cells in Bone Marrow Biopsies Is Associated with Response to Treatment in Primary Refractory AML Patients

John E. Godwin, MD, Carmen Ballesteros-Merino, PhD, Nikhil Lonberg, Shawn Jensen, PhD, Tarsem Moudgil, Carlo B Bifulco, MD, Jon Wigginton, MD, John Muth, MS, Jan K Davidson-Moncada, MD PhD, Bernard Fox, PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1410.
https://doi.org/10.1182/blood-2019-128485
Published: 2019
Journal Articles

Development and Performance of Risk Stratification Models for AML Patients Utilizing ELN-2017 Guidelines and Additional Prognostic Factors: A SWOG Report

Era L Pogosova-Agadjanyan, BS, Anna Moseley, M.S., Megan Othus, PhD, Frederick R. Appelbaum, MD, Thomas R. Chauncey, MD PhD, I-Ming L. Chen, DVM, MS, Harry P. Erba, MD PhD, John E. Godwin, MD, Isaac C. Jenkins, MS, Min Fang, MD PhD, Mike Huynh, Kenneth J Kopecky, Alan F. List, MD, Jasmine Naru, PhD, Jerald P. Radich, MD, Emily Stevens, MD PhD, Brooke E Willborg, BS, Cheryl L. Willman, MD, Brent L Wood, MD PhD, Qing Zhang, Soheil Meshinchi, MD PhD, Derek Stirewalt, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2691.
https://doi.org/10.1182/blood-2019-124529
Published: 2019
Journal Articles

Increasing Lengths of First Complete Remission with 7+3 Induction Chemotherapy for Acute Myeloid Leukemia over the Past Four Decades: Analysis of SWOG Trial Data

Megan Othus, PhD, Guillermo Garcia-Manero, MD, John E. Godwin, MD, James K. Weick, MD, Frederick R. Appelbaum, MD, Harry P. Erba, MD PhD, Elihu H. Estey, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 291.
https://doi.org/10.1182/blood-2019-127356
Published: 2019
Journal Articles

Maintenance Decitabine (DAC) Improves Disease-Free (DFS) and Overall Survival (OS) after Intensive Therapy for Acute Myeloid Leukemia (AML) in Older Adults, Particularly in FLT3-ITD-Negative Patients: ECOG-ACRIN (E-A) E2906 Randomized Study

James M. Foran, MD, Zhuoxin Sun, David F. Claxton, MD, Hillard M Lazarus, MD, Daniel A. Arber, MD, Jacob M. Rowe, MB, BS, Elisabeth Paietta, PhD, Janis Racevskis, PhD, Jessica K. Altman, Selina M. Luger, MD FRCPC, Aref Al-Kali, MD, Hong Zheng, MD PhD, Keith W. Pratz, MD, Edward R. Broun, MD, Bayard L Powell, MD, Kristen Marie O'Dwyer, MD, John E. Godwin, MD, Yishai Ofran, MD, Mark Litzow, MD, Martin S. Tallman, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 115.
https://doi.org/10.1182/blood-2019-129876
Published: 2019
Journal Articles

Improvement in Cytokine Release Syndrome Management for the Treatment of AML Patients with Flotetuzumab, a CD123 x CD3 Bispecific Dart® Molecule for T-Cell Redirected Therapy

Ouiam Bakkacha, MD, Geoffrey L. Uy, MD, Ibrahim Aldoss, MD, Matthew C Foster, MD, David A Sallman, MD, Kendra L. Sweet, MD, David A. Rizzieri, MD, Peter H. Sayre, MD PhD, Anjali S. Advani, MD, Ashkan Emadi, MD, Matthew J. Wieduwilt, MD PhD, Norbert Vey, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Tamara Moyo, MD PhD, Martha L. Arellano, MD, John E. Godwin, MD, Bob Löwenberg, MD PhD, Gerwin Huls, MD PhD, Farhad Ravandi, MD, Kathy Tran, John Muth, MS, Jan Baughman, MPH, Mojca Jongen-Lavrencic, MD PhD, Erin Timmeny, Max S. Topp, MD, Stefania Paolini, MD PhD, Kuo Guo, MSc, Teia Curtis, Jian Zhao, PhD, Jon Wigginton, MD, Ezio Bonvini, MD, Roland B. Walter, MD PhD MS, Jan Davidson, John F. DiPersio, MD PhD, Kenneth Jacobs, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 5144.
https://doi.org/10.1182/blood-2019-127138
Published: 2019
Journal Articles

Flotetuzumab, an Investigational CD123 x CD3 Bispecific Dart® Protein, in Salvage Therapy for Primary Refractory and Early Relapsed Acute Myeloid Leukemia (AML) Patients

Geoffrey L. Uy, MD, Ibrahim Aldoss, MD, Matthew C Foster, MD, David A Sallman, MD, Kendra L. Sweet, MD, David A. Rizzieri, MD, Peter H. Sayre, MD PhD, Anjali S. Advani, MD, Ashkan Emadi, MD, Matthew J. Wieduwilt, MD PhD, Norbert Vey, MD PhD, Fabio Ciceri, MD, Matteo Giovanni Carrabba, MD, Tamara Moyo, MD PhD, Sarah E. Church, PhD, Michael P. Rettig, PhD, Martha L. Arellano, MD, John E. Godwin, MD, Bob Löwenberg, MD PhD, Gerwin Huls, MD PhD, Farhad Ravandi, MD, John Muth, MS, Kathy Tran, Mojca Jongen-Lavrencic, MD PhD, Erin Timmeny, Max S. Topp, MD, Stefania Paolini, MD PhD, Kuo Guo, MSc, Teia Curtis, Jian Zhao, PhD, Jayakumar Vadakekolathu, PhD, Jon M. Wigginton, MD, Ezio Bonvini, MD, Sergio Rutella, MDPhDFRCPath, Roland B. Walter, MD PhD MS, Jan K Davidson-Moncada, MD PhD, John F. DiPersio, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 733.
https://doi.org/10.1182/blood-2019-122073
Published: 2019
Journal Articles

North American Leukemia, Intergroup Phase III Randomized Trial of Single Agent Clofarabine As Induction and Post-Remission Therapy, and Decitabine As Maintenance Therapy in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥60 Years): A Trial of the ECOG-ACRIN Cancer Research Group (E2906)

James M. Foran, MD, Zhuoxin Sun, PhD, David F. Claxton, MD, Hillard M. Lazarus, MD, Mary L. Thomas, RN, MS, Ari Melnick, MD, Ross L. Levine, MD, Elisabeth Paietta, PhD, Daniel Arber, Yangming Zhang, MD, Jacob M. Rowe, MD, John E. Godwin, MD MS, Jessica K. Altman, MD, Selina Luger, MD, Aref Al-Kali, MD, Hong Zheng, MD PhD, Keith Pratz, MD, E. Randolph Broun, MD, Bayard L. Powell, MD, Kristen O'Dwyer, MD, Mark R Litzow, MD, Martin S Tallman, MD
Journal: Blood
Blood (2015) 126 (23): 217.
https://doi.org/10.1182/blood.V126.23.217.217
Published: 2015
Journal Articles

Prognostic Significance Of NPM1 mutations In The Absence Of FLT3 -ITD in Older Patients With AML: A SWOG Report

Fabiana Ostronoff, MD, Megan Othus, PhD, Soheil Meshinchi, MD, PhD, John E. Godwin, MD, MS, Kenneth J. Kopecky, PhD, Alan List, MD, Vivian G. Oehler, MD, Stephen Petersdorf, MD, Era L. Pogosova-Agadjanyan, Jerald Radich, MD, Cheryl L. Willman, MD, Frederick R. Appelbaum, MD, Derek L. Stirewalt, MD
Journal: Blood
Blood (2013) 122 (21): 1315.
https://doi.org/10.1182/blood.V122.21.1315.1315
Published: 2013
Journal Articles

A Phase II Trial of Azacitidine (NSC-102816) and Gemtuzumab Ozogamicin (NSC-720568) As Induction and Post-Remission Therapy in Patients of Age 60 and Older with Previously Untreated Non-M3 Acute Myeloid Leukemia (SWOG S0703): Report On the Poor Risk Patients

Sucha Nand, MD, Megan Othus, PhD, John E. Godwin, MD, MS, Cheryl L Willman, MD, Thomas Norwood, Harry Paul Erba, MD, PhD, Dianna Howard, MD, Steven E. Coutre, MD, Frederick R. Appelbaum, MD
Journal: Blood
Blood (2012) 120 (21): 3584.
https://doi.org/10.1182/blood.V120.21.3584.3584
Published: 2012
Journal Articles

A Scoring System for Prediction of FLT3 -ITD Positivity in Patients with Newly Diagnosed Acute Myeloid Leukemia.

Fabiana Ostronoff, MD, Megan Othus, PhD, Hagop M. Kantarjian, MD, Soheil Meshinchi, MD, PhD, Farhad Ravandi, MD, Paul C. Hendrie, MD, PhD, Stefan Faderl, MD, Pamela S. Becker, MD, PhD, Jorge E. Cortes, MD, John M. Pagel, MD, PhD, Stephen Petersdorf, MD, John E. Godwin, MD, MS, Cheryl L Willman, MD, Sherry A. Pierce, RN, BS, Alan F List, MD, Ravinder K Sandhu, MD, Roland B. Walter, MD, PhD, Derek L. Stirewalt, MD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD
Journal: Blood
Blood (2012) 120 (21): 2590.
https://doi.org/10.1182/blood.V120.21.2590.2590
Published: 2012
Journal Articles

Prognostic Import of French-American-British (FAB) System As Embedded in 2008 Revision of World Health Organization Classification of AML: Review of SWOG Data

Laura F Newell, MD, Megan Othus, PhD, Roland B. Walter, MD, PhD, Stephen H. Petersdorf, MD, Thomas Chauncey, MD, PhD, Jeanne E. Anderson, MD, John E. Godwin, MD, MS, Kenneth J. Kopecky, PhD, Frederick R. Appelbaum, MD, Elihu H. Estey, MD
Journal: Blood
Blood (2011) 118 (21): 1446.
https://doi.org/10.1182/blood.V118.21.1446.1446
Published: 2011
Journal Articles

KIT Mutations Are Rare Among Elderly AML Patients: A SWOG Report

Fabiana Ostronoff, MD, Megan Othus, PhD, Phoenix A. Ho, MD, Stephen H. Petersdorf, MD, Jeanne E. Anderson, MD, John E. Godwin, MD, MS, Cheryl L Willman, MD, Jerald P. Radich, MD, Frederick R. Appelbaum, MD, Derek L. Stirewalt, MD, Soheil Meshinchi, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 2510.
https://doi.org/10.1182/blood.V118.21.2510.2510
Published: 2011
Journal Articles

Prevalence and Clinical Implications of IDH2 R140 and R172 Mutations in Older Adults with AML: A Report From SWOG,

Phoenix A. Ho, MD, Megan Othus, PhD, Fabiana Ostronoff, MD, Stephen H. Petersdorf, MD, Jeanne E. Anderson, MD, John E. Godwin, MD, MS, Cheryl L Willman, MD, Jerald P. Radich, MD, Frederick R. Appelbaum, MD, Derek L. Stirewalt, MD, Soheil Meshinchi, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 3516.
https://doi.org/10.1182/blood.V118.21.3516.3516
Published: 2011
Journal Articles

DNMT3A Mutations Independently Predict Poor Outcome in Older AML Patients: A SWOG Report,

Fabiana Ostronoff, MD, Megan Othus, PhD, Phoenix A. Ho, MD, Stephen H. Petersdorf, MD, Jeanne E. Anderson, MD, John E. Godwin, MD, MS, Cheryl L Willman, MD, Jerald P. Radich, MD, Frederick R. Appelbaum, MD, Derek L. Stirewalt, MD, Soheil Meshinchi, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 3519.
https://doi.org/10.1182/blood.V118.21.3519.3519
Published: 2011
Journal Articles

Over-Expression of Novel IRF8 Splice Variants Is Associated with a Significant Decrease In Relapse-Free Survival In Adult AML Patients.

Era L. Pogosova-Agadjanyan, Kenneth J. Kopecky, PhD, Hana Lee, Jeanne E. Anderson, MD, John E. Godwin, MD, MS, Alan F. List, Soheil Meshinchi, MD, PhD, Vivian Oehler, MD, Stephen H. Petersdorf, MD, Cheryl L. Willman, MD, Frederick R. Appelbaum, MD, Jerald P. Radich, MD, Derek L. Stirewalt, MD
Journal: Blood
Blood (2010) 116 (21): 1679.
https://doi.org/10.1182/blood.V116.21.1679.1679
Published: 2010